GSK Begins RFID Pilot Program
GSK Begins RFID Pilot Program
GlaxoSmithKline PLC (GSK, London, England, www.gsk.com) has begun distributing its “Trizivir” HIV drug with radio frequency identification (RFID) technology as part of a pilot project. The tags will be placed on all bottles of Trizivir distributed in the United States. Trizivir is a fixed-dose combination of GSK’s “Ziagen” (abacavir/ABC), “Retrovir” (zidovudine/AZT), and Epivir (lamivudine/3TC) therapies.
RFID-tagged bottles of Trizivir will begin appearing on pharmacists’ shelves in mid-April. GSK says it is working closely with FDA to assess the technology and its prospects for reducing counterfeiting. The testing of the RFID technology on additional products will be evaluated by GSK with guidance from FDA as the Trizivir pilot progresses.
GSK has worked with IBM (White Plains, NY, www.ibm.com) to design and build the technology in the pilot program, which allows GSK to tag each bottle with a unique product code.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Drug Packaging and Sustainability Essentials
April 4th 2023Lon Johnson, VP of Sales and Marketing at Colbert Packaging Corporation, discusses the latest drug packaging updates and how companies can become more sustainable with Pharmaceutical Technology editor Jill Murphy.
